Advertisement

Epidemiology of De Novo Metastatic Breast Cancer

Published:January 31, 2021DOI:https://doi.org/10.1016/j.clbc.2021.01.017

      Abstract

      Most cases of metastatic breast cancer (MBC) arise as a recurrence of a previously treated early breast cancer. Distinct from recurrent MBC is de novo MBC (dnMBC), which describes patients who present with distant sites of disease at initial diagnosis and is reviewed here. dnMBC represents approximately 3% to 6% of new breast cancer diagnoses in high-income countries. This incidence has not declined despite decades of widespread use of population-based mammography screening. Overrepresentation of both biologically aggressive tumors and patients negatively impacted by social determinants of health are characteristics of dnMBC. Survival has generally been superior for patients with dnMBC compared with those with recurrent MBC, although it is similar to that for patients with recurrent MBC with long disease-free intervals. Subgroups of patients with dnMBC who experience prolonged survival include those with human epidermal growth factor receptor-2–positive disease or hormone receptor–positive bone-only disease. Opportunities to decrease dnMBC presentation may include novel screening modalities suited for biologically aggressive breast tumors and improved access to health care. Recognizing that there will remain some women diagnosed with dnMBC, refining our ability to identify those likely to be long-term survivors could allow for appropriate escalation or de-escalation of care. Finally, evaluation of tumor genomics in robust sample sizes has the potential to advance our knowledge of the biology of dnMBC as an entity distinct from recurrent MBC.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tao L
        • Chu L
        • Wang LI
        • et al.
        Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.
        Cancer Causes Control. 2016; 27: 1127-1138
        • Howlader N
        • Cronin KA
        • Kurian AW
        • Andridge R.
        Differences in breast cancer survival by molecular subtypes in the United States.
        Cancer Epidemiol Biomarkers Prev. 2018; 27: 619-626
        • Heller DR
        • Chiu AS
        • Farrell K
        • Killelea BK
        • Lannin DR.
        Why has breast cancer screening failed to decrease the incidence of de novo stage IV disease?.
        Cancers (Basel). 2019; 11: 500
        • Anderson BO
        • Cazap E
        • El Saghir NS
        • et al.
        Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010.
        Lancet Oncol. 2011; 12: 387-398
        • Jacklyn G
        • McGeechan K
        • Irwig L
        • et al.
        Trends in stage-specific breast cancer incidence in New South Wales, Australia: insights into the effects of 25 years of screening mammography.
        Breast Cancer Res Treat. 2017; 166: 843-854
        • Cortesi L
        • Toss A
        • Cirilli C
        • et al.
        Twenty-years experience with de novo metastatic breast cancer.
        Int J Cancer. 2015; 137: 1417-1426
        • Dey S
        • Soliman AS
        • Hablas A
        • et al.
        Urban-rural differences in breast cancer incidence by hormone receptor status across 6 years in Egypt.
        Breast Cancer Res Treat. 2010; 120: 149-160
        • Malmgren JA
        • Mayer M
        • Atwood MK
        • Kaplan HG.
        Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
        Breast Cancer Res Treat. 2018; 167: 579-590
        • Nair N
        • Shet T
        • Parmar V
        • et al.
        Breast cancer in a tertiary cancer center in India - an audit, with outcome analysis.
        Indian J Cancer. 2018; 55: 16-22
        • Weiner CM
        • Mathewos A
        • Addissie A
        • et al.
        Characteristics and follow-up of metastatic breast cancer in Ethiopia: a cohort study of 573 women.
        Breast. 2018; 42: 23-30
        • Friedman LC
        • Kalidas M
        • Elledge R
        • et al.
        Medical and psychosocial predictors of delay in seeking medical consultation for breast symptoms in women in a public sector setting.
        J Behav Med. 2006; 29: 327-334
        • Moodley J
        • Cairncross L
        • Naiker T
        • Constant D.
        From symptom discovery to treatment–women's pathways to breast cancer care: a cross-sectional study.
        BMC Cancer. 2018; 18: 312
        • Lycette J.
        Neglected–cancer care and mental health in rural America.
        N Engl J Med. 2016; 375: 2220-2221
        • Jassem J
        • Ozmen V
        • Bacanu F
        • et al.
        Delays in diagnosis and treatment of breast cancer: a multinational analysis.
        Eur J Public Health. 2014; 24: 761-767
        • Mariotto AB
        • Etzioni R
        • Hurlbert M
        • Penberthy L
        • Mayer M.
        Estimation of the number of women living with metastatic breast cancer in the United States.
        Cancer Epidemiol Biomarkers Prev. 2017; 26: 809-815
        • Di Meglio A
        • Freedman RA
        • Lin NU
        • et al.
        Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis.
        Breast Cancer Res Treat. 2016; 157: 587-596
        • Bleyer A
        • Welch HG.
        Effect of three decades of screening mammography on breast-cancer incidence.
        N Engl J Med. 2012; 367: 1998-2005
        • Verdial FC
        • Etzioni R
        • Duggan C
        • Anderson BO.
        Demographic changes in breast cancer incidence, stage at diagnosis and age associated with population-based mammographic screening.
        J Surg Oncol. 2017; 115: 517-522
        • Esserman L
        • Shieh Y
        • Thompson I.
        Rethinking screening for breast cancer and prostate cancer.
        JAMA. 2009; 302: 1685-1692
        • Welch HG
        • Gorski DH
        • Albertsen PC.
        Trends in metastatic breast and prostate cancer–lessons in cancer dynamics.
        N Engl J Med. 2015; 373: 1685-1687
        • Sparano J
        • O'Neill A
        • Alpaugh K
        • et al.
        Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial.
        JAMA Oncol. 2018; 4: 1700-1706
        • Garcia-Murillas I
        • Chopra N
        • Comino-Mendez I
        • et al.
        Assessment of molecular relapse detection in early-stage breast cancer.
        JAMA Oncol. 2019; 5: 1473-1478
        • Trapp E
        • Janni W
        • Schindlbeck C
        • et al.
        Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis.
        J Natl Cancer Inst. 2019; 111: 380-387
        • Parsons HA
        • Rhoades J
        • Reed SC
        • et al.
        Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer.
        Clin Cancer Res. 2020; 26: 2556-2564
        • Ignatiadis M
        • Lee M
        • Jeffrey SS.
        Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility.
        Clin Cancer Res. 2015; 21: 4786-4800
        • Porter AJ
        • Evans EB
        • Foxcroft LM
        • Simpson PT
        • Lakhani SR.
        Mammographic and ultrasound features of invasive lobular carcinoma of the breast.
        J Med Imaging Radiat Oncol. 2014; 58: 1-10
        • Ravaioli A
        • Pasini G
        • Polselli A
        • et al.
        Staging of breast cancer: new recommended standard procedure.
        Breast Cancer Res Treat. 2002; 72: 53-60
        • Brothers JM
        • Kidwell KM
        • Brown RK
        • Henry NL.
        Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrence.
        Breast Cancer Res Treat. 2016; 155: 395-403
        • Puglisi F
        • Follador A
        • Minisini AM
        • et al.
        Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications.
        Ann Oncol. 2005; 16: 263-266
        • Myers RE
        • Johnston M
        • Pritchard K
        • Levine M
        • Oliver T
        Breast Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. Baseline staging tests in primary breast cancer: a practice guideline.
        CMAJ. 2001; 164: 1439-1444
        • Ciatto S
        • Pacini P
        • Azzini V
        • et al.
        Preoperative staging of primary breast cancer. A multicentric study.
        Cancer. 1988; 61: 1038-1040
        • Brennan ME
        • Houssami N.
        Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer.
        Breast. 2012; 21: 112-123
        • Ciatto S
        • Pacini P
        • Azzini V
        • et al.
        Preoperative staging of primary breast cancer. A multicentric study.
        Cancer. 1988; 61: 1038-1040
      1. Network NCC. Breast Cancer (Version 6.2020).

        • Schnipper LE
        • Smith TJ
        • Raghavan D
        • et al.
        American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology.
        J Clin Oncol. 2012; 30: 1715-1724
        • Press DJ
        • Miller ME
        • Liederbach E
        • Yao K
        • Huo D.
        De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
        Clin Exp Metastasis. 2017; 34: 457-465
        • Wang R
        • Zhu Y
        • Liu X
        • Liao X
        • He J
        • Niu L.
        The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer.
        BMC Cancer. 2019; 19: 1091
        • Lobbezoo DJ
        • van Kampen RJ
        • Voogd AC
        • et al.
        Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?.
        Br J Cancer. 2015; 112: 1445-1451
        • Leone BA
        • Vallejo CT
        • Romero AO
        • et al.
        Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis.
        Breast Cancer Res Treat. 2017; 161: 537-548
        • Plichta JK
        • Thomas SM
        • Sergesketter AR
        • et al.
        A novel staging system for de novo metastatic breast cancer refines prognostic estimates [e-pub ahead of print].
        Ann Surg. 2021; (accessed)https://doi.org/10.1097/SLA.0000000000004231
        • Dawood S
        • Broglio K
        • Ensor J
        • Hortobagyi GN
        • Giordano SH.
        Survival differences among women with de novo stage IV and relapsed breast cancer.
        Ann Oncol. 2010; 21: 2169-2174
        • Hellman S
        • Weichselbaum RR.
        Oligometastases.
        J Clin Oncol. 1995; 13: 8-10
        • Polednak AP.
        Increase in distant stage breast cancer incidence rates in US women aged 25–49 years, 2000–2011: the stage migration hypothesis.
        J Cancer Epidemiol. 2015; 2015710106
        • Seltzer S
        • Corrigan M
        • O'Reilly S
        The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer.
        Exp Mol Pathol. 2020; 114104404
        • Amey CH
        • Miller MK
        • Albrecht SL.
        The role of race and residence in determining stage at diagnosis of breast cancer.
        J Rural Health. 1997; 13: 99-108
        • Williams F
        • Thompson E.
        Disparity in breast cancer late stage at diagnosis in Missouri: does rural versus urban residence matter?.
        J Racial Ethn Health Disparities. 2016; 3: 233-239
        • Baade PD
        • Turrell G
        • Aitken JF.
        Geographic remoteness, area-level socio-economic disadvantage and advanced breast cancer: a cross-sectional, multilevel study.
        J Epidemiol Community Health. 2011; 65: 1037-1043
        • MacKinnon JA
        • Duncan RC
        • Huang Y
        • et al.
        Detecting an association between socioeconomic status and late stage breast cancer using spatial analysis and area-based measures.
        Cancer Epidemiol Biomarkers Prev. 2007; 16: 756-762
        • Dalton SO
        • During M
        • Ross L
        • et al.
        The relation between socioeconomic and demographic factors and tumour stage in women diagnosed with breast cancer in Denmark, 1983-1999.
        Br J Cancer. 2006; 95: 653-659
        • Friedell GH
        • Linville LH
        • Sorrell CL
        • Huang B.
        Kentucky breast cancer report card.
        J Ky Med Assoc. 2003; 101: 449-454
        • Hausauer AK
        • Keegan TH
        • Chang ET
        • Glaser SL
        • Howe H
        • Clarke CA.
        Recent trends in breast cancer incidence in US white women by county-level urban/rural and poverty status.
        BMC Med. 2009; 7: 31
        • Bhoo-Pathy N
        • Verkooijen HM
        • Tan EY
        • et al.
        Trends in presentation, management and survival of patients with de novo metastatic breast cancer in a Southeast Asian setting.
        Sci Rep. 2015; 5: 16252
        • Olivotto IA
        • Mates D
        • Kan L
        • Fung J
        • Samant R
        • Burhenne LJ.
        Prognosis, treatment, and recurrence of breast cancer for women attending or not attending the Screening Mammography Program of British Columbia.
        Breast Cancer Res Treat. 1999; 54: 73-81
        • Blair SL
        • Sadler GR
        • Bristol R
        • Summers C
        • Tahar Z
        • Saltzstein SL.
        Early cancer detection among rural and urban Californians.
        BMC Public Health. 2006; 6: 194
        • Henry KA
        • Boscoe FP
        • Johnson CJ
        • Goldberg DW
        • Sherman R
        • Cockburn M.
        Breast cancer stage at diagnosis: is travel time important?.
        J Community Health. 2011; 36: 933-942
        • Nguyen-Pham S
        • Leung J
        • McLaughlin D.
        Disparities in breast cancer stage at diagnosis in urban and rural adult women: a systematic review and meta-analysis.
        Ann Epidemiol. 2014; 24: 228-235
        • Cardoso F
        • Di LA
        • Lohrisch C
        • Bernard C
        • Ferreira F
        • Piccart MJ.
        Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?.
        Ann Oncol. 2002; 13: 197-207
        • Chia SK
        • Speers CH
        • D'Yachkova Y
        • et al.
        The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.
        Cancer. 2007; 110: 973-979
        • Gennari A
        • Conte P
        • Rosso R
        • Orlandini C
        • Bruzzi P.
        Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies.
        Cancer. 2005; 104: 1742-1750
        • Dafni U
        • Grimani I
        • Xyrafas A
        • Eleftheraki AG
        • Fountzilas G.
        Fifteen-year trends in metastatic breast cancer survival in Greece.
        Breast Cancer Res Treat. 2010; 119: 621-631
        • Aparicio S
        • Caldas C.
        The implications of clonal genome evolution for cancer medicine.
        N Engl J Med. 2013; 368: 842-851
        • Caldas C.
        Cancer sequencing unravels clonal evolution.
        Nat Biotechnol. 2012; 30: 408-410
        • den Brok WD
        • Speers CH
        • Gondara L
        • Baxter E
        • Tyldesley SK
        • Lohrisch CA.
        Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
        Breast Cancer Res Treat. 2017; 161: 549-556
        • Lambertini M
        • Ferreira AR
        • Di Meglio A
        • et al.
        Patterns of care and clinical outcomes of HER2-positive metastatic breast cancer patients with newly diagnosed stage IV or recurrent disease undergoing first-line trastuzumab-based therapy: a multicenter retrospective cohort study.
        Clin Breast Cancer. 2017; 17 (.e2): 601-610
        • Yamamura J
        • Kamigaki S
        • Fujita J
        • Osato H
        • Komoike Y.
        The difference in prognostic outcomes between.
        In Vivo. 2018; 32: 353-358
        • Yardley DA
        • Kaufman PA
        • Brufsky A
        • et al.
        Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
        Breast Cancer Res Treat. 2014; 145: 725-734
        • Kitagawa D
        • Horiguchi S
        • Yamashita T
        • Kuroi K
        • Shimizu K.
        Comparison of outcomes between women with de novo stage IV and relapsed breast cancer.
        J Nippon Med Sch. 2014; 81: 139-147
        • Caswell-Jin JL
        • Plevritis SK
        • Tian L
        • et al.
        Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review.
        JNCI Cancer Spectr. 2018; 2: pky062
        • Elfgen C
        • Montagna G
        • Schmid SM
        • Bierbauer W
        • Güth U.
        Metastatic breast cancer as a chronic disease: evidence-based data on a theoretical concept.
        Breast Care (Basel). 2020; 15: 281-288
        • Güth U
        • Elfgen C
        • Montagna G
        • Schmid SM.
        Long-term survival and cure in distant metastatic breast cancer.
        Oncology. 2019; 97: 82-93
        • Klar N
        • Rosenzweig M
        • Diergaarde B
        • Brufsky A.
        Features associated with long-term survival in patients with metastatic breast cancer.
        Clin Breast Cancer. 2019; 19: 304-310
        • Andre F
        • Slimane K
        • Bachelot T
        • et al.
        Breast cancer with synchronous metastases: trends in survival during a 14-year period.
        J Clin Oncol. 2004; 22: 3302-3308
        • Dawood S
        • Broglio K
        • Gonzalez-Angulo AM
        • Buzdar AU
        • Hortobagyi GN
        • Giordano SH.
        Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer.
        J Clin Oncol. 2008; 26: 4891-4898
        • Wong Y
        • Raghavendra AS
        • Hatzis C
        • et al.
        Long-term survival of de novo stage IV human epidermal growth receptor 2 (HER2) positive breast cancers treated with HER2-targeted therapy.
        Oncologist. 2019; 24: 313-318
        • O'Shaughnessy J
        • Petrakova K
        • Sonke GS
        • et al.
        Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
        Breast Cancer Res Treat. 2018; 168: 127-134
        • Finn RS
        • Martin M
        • Rugo HS
        • et al.
        Palbociclib and letrozole in advanced breast cancer.
        N Engl J Med. 2016; 375: 1925-1936
        • Di Leo A
        • O'Shaughnessy J
        • Sledge Jr, GW
        • et al.
        Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy.
        NPJ Breast Cancer. 2018; 4: 41
        • Slamon DJ
        • Neven P
        • Chia S
        • et al.
        Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3.
        J Clin Oncol. 2018; 36: 2465-2472
        • Wolmark N.
        Bernard Fisher, 1918-2019.
        J Clin Oncol. 2020; 38: 1751-1756